GlassScriptPhysician profile
Amer H Abbas
NPI 1508480666
$3,203.30
in general payments reported to CMS, 2019-2025
22 companies · $595 in 2025
The $595 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $1,578 · 2023: $367 · 2024: $413 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.26 |
| Education | $356.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $1,200.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $319.53 | 2023-2025 | Camzyos |
| Abbott Laboratories | $253.33 | 2024-2025 | Ensite, Agilis |
| Amgen INC. | $179.28 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $170.34 | 2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Hawkone |
| Janssen Pharmaceuticals, INC | $155.75 | 2021-2024 | Xarelto |
| Pfizer INC. | $137.79 | 2022-2025 | |
| Nevro Corp. | $123.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $107.95 | 2021 | |
| Genzyme Corporation | $99.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $86.11 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.01 | 2022 | |
| Alnylam Pharmaceuticals INC. | $85.38 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $71.96 | 2025 | |
| Daiichi Sankyo INC. | $21.53 | 2023 | Injectafer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $18.44 | 2023 | Hizentra |
| Gilead Sciences, INC. | $18.10 | 2023 | Epclusa |
| Arbor Pharmaceuticals, INC. | $17.25 | 2021 | |
| Glaxosmithkline, LLC. | $16.64 | 2023 | Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.12 | 2023-2025 | Lifevest |
| Biotronik INC. | $13.17 | 2024 | Recross |
| Zoll Circulation INC | $7.00 | 2023 | Catheter, Temperature Management System, Temperature Management System Start-Up Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.